Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DM90BJ
|
|||
| Drug Name |
AAV-CNGA3
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Achromatopsia [ICD-11: 9B70; ICD-10: H53.51] | Phase 1/2 | [1] | |
| Company |
Janssen; MeiraGTx
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclic nucleotide-gated channel alpha-3 (CNGA3) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03758404) Gene Therapy for Achromatopsia (CNGA3) (CNGA3). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of MeiraGTx. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.